Transarterial Chemoembolization
Transarterial Chemoembolization - Related Videos
08:55
Transarterial Administration of Oncolytic Viruses for Locoregional Therapy of Orthotopic HCC in Rats
0 Views •
Cited by 3 •
2016
Oncolytic virotherapies are under development as novel therapeutics for the treatment of hepatocellular carcinoma (HCC). Here we describe a method for locoregional therapy of HCC via hepatic arterial administration of oncolytic virus.
05:31
Transradial Access Chemoembolization for Hepatocellular Carcinoma Patients
0 Views •
Cited by 2 •
2020
Transarterial chemoembolization (TACE) is the standard therapy for patients in the intermediate stage of hepatocellular carcinoma and is typically performed through femoral artery access. Compared with transfemoral access, transradial access (TRA) can decrease the rate of bleeding complications and improve patient tolerance. A method is presented here to perform transarterial chemoembolization via radial artery access.
09:49
Dual-phase Cone-beam Computed Tomography to See, Reach, and Treat Hepatocellular Carcinoma during Drug-eluting Beads Transarterial Chemo-embolization
0 Views •
Cited by 22 •
2013
Dual-phase cone-beam computed tomography (DP-CBCT) is a useful intraprocedural imaging technique for transarterial chemo-embolization treatment with drug-eluting beads of hepatocellular carcinoma. DP-CBCT has been used to perform three major steps in oncologic interventional radiology: tumor localization (see), navigation and intraprocedural catheter guidance (reach), and intraprocedural evaluation of treatment success (treat).
FAQs
The two components act through complementary mechanisms. Anticancer drugs create concentrated treatment exposure at the tumor, while embolic materials restrict incoming blood flow and produce ischemia, a reduced-oxygen state caused by limited perfusion. Together, these effects can suppress tumor growth through both local drug action and vascular restriction, while the targeted approach helps limit systemic treatment effects.
Clinicians guide the catheter through the arterial system to vessels feeding the tumor. This route concentrates anticancer drug delivery at the disease site and allows embolic materials to reach the same tumor-feeding circulation. Accurate targeting therefore supports the two central treatment effects: increased local drug exposure and restricted blood flow within the tumor’s vascular supply.
Ischemia links the vascular and anticancer components of the procedure. After embolic materials restrict blood flow, the tumor experiences reduced perfusion while chemotherapy is delivered directly to the targeted area. This dual pressure can help control tumor growth and reduce tumor burden. The treatment response therefore depends not only on drug action but also on limiting the tumor’s blood supply.
The procedure is designed to increase anticancer drug exposure at the tumor while restricting blood flow to its feeding vessels. This local delivery strategy concentrates treatment at the disease site rather than distributing it broadly throughout the body, helping limit systemic effects while preserving a direct antitumor action. That balance supports targeted, minimally invasive intervention in cancer care.
A catheter provides the route through the arterial system, anticancer drugs supply the local chemotherapy, and embolic materials create the intended vascular blockage. The catheter is guided to vessels feeding the tumor before the therapeutic components are injected. Their ordered use connects vascular access, local drug exposure, and ischemia within one minimally invasive intervention.
The source material identifies liver cancer as the setting in which TACE is especially important. Its clinical roles include controlling tumor growth and reducing tumor burden. It can also serve as a bridge to surgery or transplantation, helping manage disease before one of those treatments. These roles place the procedure within the broader field of interventional oncology.
TACE provides a model for studying how local drug delivery and vascular restriction can be combined in interventional oncology. Researchers can examine tumor control, reduced burden, local exposure, ischemia, and systemic treatment effects as connected outcomes. Its role as a bridge to surgery or transplantation also makes it relevant to research on coordinated care for liver cancer.